BidaskClub upgraded shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) from a sell rating to a hold rating in a report published on Friday morning.
DPLO has been the topic of a number of other research reports. Bank of America Corporation increased their price objective on Diplomat Pharmacy from $17.00 to $18.50 and gave the company a neutral rating in a report on Thursday, May 25th. Needham & Company LLC began coverage on Diplomat Pharmacy in a report on Friday, July 21st. They issued a buy rating and a $19.75 price objective on the stock. Zacks Investment Research downgraded Diplomat Pharmacy from a hold rating to a sell rating in a report on Monday, July 17th. Finally, TheStreet raised Diplomat Pharmacy from a d+ rating to a c- rating in a research report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of Hold and an average target price of $17.89.
Shares of Diplomat Pharmacy (NYSE DPLO) traded up 0.97% during midday trading on Friday, reaching $19.68. The company’s stock had a trading volume of 1,822,893 shares. Diplomat Pharmacy has a 12-month low of $12.25 and a 12-month high of $31.33. The company has a market cap of $1.34 billion, a P/E ratio of 107.54 and a beta of 0.65. The stock’s 50-day moving average price is $16.70 and its 200-day moving average price is $16.22.
Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings data on Monday, August 7th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 7.97% and a net margin of 0.27%. The business had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.14 billion. During the same quarter in the prior year, the business posted $0.23 EPS. The business’s revenue for the quarter was up 3.5% on a year-over-year basis. On average, analysts expect that Diplomat Pharmacy will post $0.75 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in DPLO. JPMorgan Chase & Co. boosted its position in shares of Diplomat Pharmacy by 73.1% in the 1st quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock valued at $116,000 after purchasing an additional 3,056 shares during the period. State of Alaska Department of Revenue boosted its position in shares of Diplomat Pharmacy by 80.0% in the 2nd quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock valued at $127,000 after purchasing an additional 3,833 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Diplomat Pharmacy by 46.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after purchasing an additional 2,794 shares during the period. BNP Paribas Arbitrage SA boosted its position in shares of Diplomat Pharmacy by 13.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 8,876 shares of the company’s stock valued at $142,000 after purchasing an additional 1,073 shares during the period. Finally, Municipal Employees Retirement System of Michigan boosted its position in shares of Diplomat Pharmacy by 4.9% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock valued at $152,000 after purchasing an additional 480 shares during the period. 69.89% of the stock is owned by hedge funds and other institutional investors.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.